Nifty
Sensex
:
:
11662.60
39131.04
74.25 (0.64%)
234.33 (0.60%)

Pharmaceuticals & Drugs

Rating :
48/99  (View)

BSE: 524715 | NSE: SUNPHARMA

433.30
10.35 (2.45%)
16-Jul-2019 | 3:59PM
  • Day's Open
  • Day's High
  • Day's Low
  • Previous Close
  •  420.80
  •  435.00
  •  418.65
  •  422.95
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  8630766
  •  37397.11
  •  679.30
  •  344.55

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 101,347.91
  • 38.02
  • 1
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 101,803.80
  • 0.47%
  • 2.45

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 54.38%
  • 3.73%
  • 7.36%
  • FII
  • DII
  • Others
  • 0.88%
  • 16.38%
  • 17.27%

Chart

Price | P:E | P:BV | EV:EBITDA

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 19.98
  • 10.44
  • -2.05

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 11.50
  • -4.48
  • -7.47

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 1.87
  • -6.99
  • -21.63

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 33.98
  • 38.93
  • 33.66

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 5.53
  • 5.23
  • 3.62

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 18.17
  • 18.75
  • 15.87

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 19
Mar 18
Var%
Dec 18
Dec 17
Var%
Sep 18
Sep 17
Var%
Jun 18
Jun 17
Var%
Net Sales
7,163.92
6,977.10
2.68%
7,740.19
6,653.23
16.34%
6,937.63
6,650.34
4.32%
7,224.17
6,208.79
16.35%
Expenses
6,147.13
5,293.61
16.12%
5,587.30
5,199.85
7.45%
5,406.42
5,274.73
2.50%
5,617.47
5,113.14
9.86%
EBITDA
1,016.79
1,683.49
-39.60%
2,152.89
1,453.38
48.13%
1,531.21
1,375.61
11.31%
1,606.70
1,095.65
46.64%
EBIDTM
14.19%
24.13%
27.81%
21.84%
22.07%
20.68%
22.24%
17.65%
Other Income
281.53
302.75
-7.01%
193.06
129.19
49.44%
351.15
254.84
37.79%
199.75
151.98
31.43%
Interest
150.03
155.38
-3.44%
144.79
95.33
51.88%
129.53
157.44
-17.73%
130.90
109.42
19.63%
Depreciation
454.05
455.24
-0.26%
471.05
339.32
38.82%
426.51
358.65
18.92%
401.64
346.63
15.87%
PBT
694.24
1,375.62
-49.53%
1,730.11
1,147.92
50.72%
111.94
1,114.36
-89.95%
1,273.91
-158.92
-
Tax
-28.81
-176.69
-
270.92
792.52
-65.82%
218.91
111.40
96.51%
163.86
161.78
1.29%
PAT
723.05
1,552.31
-53.42%
1,459.19
355.40
310.58%
-106.97
1,002.96
-
1,110.05
-320.70
-
PATM
10.09%
22.25%
18.85%
5.34%
-1.54%
15.08%
15.37%
-5.17%
EPS
2.65
5.46
-51.47%
5.18
1.34
286.57%
-0.91
3.80
-
4.09
-1.77
-

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Mar 09
Net Sales
29,065.91
26,415.54
31,308.14
28,108.61
27,392.01
16,080.36
11,299.86
8,019.49
5,727.90
4,007.45
4,272.30
Net Sales Growth
9.73%
-15.63%
11.38%
2.62%
70.34%
42.31%
40.90%
40.01%
42.93%
-6.20%
 
Cost Of Goods Sold
7,868.97
7,318.73
8,164.20
6,170.19
6,732.84
2,777.68
2,076.36
1,647.61
1,460.40
1,098.45
848.40
Gross Profit
21,196.94
19,096.81
23,143.94
21,938.42
20,659.17
13,302.68
9,223.50
6,371.88
4,267.50
2,909.00
3,423.90
GP Margin
72.93%
72.29%
73.92%
78.05%
75.42%
82.73%
81.62%
79.45%
74.50%
72.59%
80.14%
Total Expenditure
22,758.32
20,880.73
21,625.92
19,950.29
19,615.54
9,120.95
6,437.76
4,836.43
3,785.07
2,644.63
2,408.35
Power & Fuel Cost
-
559.97
525.09
545.44
560.77
232.41
187.10
145.65
96.78
91.92
97.77
% Of Sales
-
2.12%
1.68%
1.94%
2.05%
1.45%
1.66%
1.82%
1.69%
2.29%
2.29%
Employee Cost
-
5,367.05
4,902.30
4,772.31
4,502.64
2,074.44
1,534.53
1,187.73
818.95
396.84
336.65
% Of Sales
-
20.32%
15.66%
16.98%
16.44%
12.90%
13.58%
14.81%
14.30%
9.90%
7.88%
Manufacturing Exp.
-
1,401.09
1,293.98
1,418.59
1,433.89
815.49
618.43
462.65
338.40
398.53
464.82
% Of Sales
-
5.30%
4.13%
5.05%
5.23%
5.07%
5.47%
5.77%
5.91%
9.94%
10.88%
General & Admin Exp.
-
3,288.76
3,113.67
2,956.85
2,894.97
978.48
793.38
629.48
480.66
215.47
144.49
% Of Sales
-
12.45%
9.95%
10.52%
10.57%
6.08%
7.02%
7.85%
8.39%
5.38%
3.38%
Selling & Distn. Exp.
-
1,864.55
2,520.64
2,262.35
2,236.40
1,394.78
763.01
516.55
372.14
290.33
388.60
% Of Sales
-
7.06%
8.05%
8.05%
8.16%
8.67%
6.75%
6.44%
6.50%
7.24%
9.10%
Miscellaneous Exp.
-
1,080.58
1,106.04
1,824.56
1,254.03
847.67
464.95
246.76
217.74
153.09
388.60
% Of Sales
-
4.09%
3.53%
6.49%
4.58%
5.27%
4.11%
3.08%
3.80%
3.82%
2.99%
EBITDA
6,307.59
5,534.81
9,682.22
8,158.32
7,776.47
6,959.41
4,862.10
3,183.06
1,942.83
1,362.82
1,863.95
EBITDA Margin
21.70%
20.95%
30.93%
29.02%
28.39%
43.28%
43.03%
39.69%
33.92%
34.01%
43.63%
Other Income
1,025.49
912.08
1,030.20
658.25
637.89
592.59
422.23
492.77
375.08
211.48
214.36
Interest
555.25
517.57
399.80
523.24
578.99
44.19
43.16
28.20
73.88
6.15
5.85
Depreciation
1,753.25
1,499.84
1,264.75
1,037.53
1,194.72
409.23
336.17
291.16
204.85
153.31
123.29
PBT
3,810.20
4,429.48
9,047.87
7,255.80
6,640.65
7,098.58
4,905.00
3,356.47
2,039.18
1,414.84
1,949.17
Tax
624.88
845.19
1,211.57
913.77
914.69
702.17
845.55
313.19
128.58
67.86
71.16
Tax Rate
16.40%
24.29%
13.39%
13.91%
14.29%
15.33%
19.57%
9.33%
6.31%
4.80%
3.65%
PAT
3,185.32
2,186.99
6,954.44
4,544.26
4,551.94
3,141.47
2,989.59
2,657.80
1,819.29
1,351.08
1,817.73
PAT before Minority Interest
2,642.89
2,633.79
7,836.30
5,656.86
5,488.21
3,879.00
3,475.87
3,043.28
1,910.60
1,346.98
1,878.01
Minority Interest
-542.43
-446.80
-881.86
-1,112.60
-936.27
-737.53
-486.28
-385.48
-91.31
4.10
-60.28
PAT Margin
10.96%
8.28%
22.21%
16.17%
16.62%
19.54%
26.46%
33.14%
31.76%
33.71%
42.55%
PAT Growth
22.99%
-68.55%
53.04%
-0.17%
44.90%
5.08%
12.48%
46.09%
34.65%
-25.67%
 
Unadjusted EPS
11.01
9.00
29.00
18.90
18.90
15.20
14.40
25.70
17.50
13.00
87.80

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Mar 09
Shareholder's Funds
38,100.56
36,639.67
32,982.48
25,638.09
18,524.95
14,989.73
12,235.78
9,483.32
7,828.91
7,044.92
Share Capital
239.93
239.93
240.66
207.12
207.12
103.56
103.56
103.56
103.56
103.56
Total Reserves
37,860.63
36,397.10
32,736.26
25,374.38
18,317.83
14,886.17
12,132.22
9,379.76
7,725.35
6,941.36
Non-Current Liabilities
259.98
599.87
2,169.59
2,335.46
1,748.41
199.02
-225.23
-188.27
82.11
110.99
Secured Loans
217.69
185.59
7.73
40.69
43.76
41.90
49.65
4.38
100.35
36.38
Unsecured Loans
1,554.40
1,250.49
3,102.57
1,327.73
4.91
73.36
105.77
152.90
70.80
142.51
Long Term Provisions
404.46
1,211.11
1,895.86
2,532.34
2,601.62
787.06
138.73
13.00
0.00
0.00
Current Liabilities
19,864.32
17,887.02
13,143.96
16,146.81
5,989.59
2,841.25
2,618.49
1,730.88
757.92
719.81
Trade Payables
4,766.20
4,395.39
3,582.92
3,286.54
1,328.26
1,057.99
992.72
645.38
319.44
254.34
Other Current Liabilities
1,875.93
2,673.68
1,134.27
2,279.59
260.41
218.65
363.66
362.42
90.07
122.37
Short Term Borrowings
7,979.70
6,654.92
5,206.12
6,227.92
2,440.34
82.95
109.57
207.78
0.00
0.00
Short Term Provisions
5,242.49
4,163.03
3,220.65
4,352.76
1,960.58
1,481.66
1,152.54
515.30
348.41
343.10
Total Liabilities
62,109.02
58,917.42
52,381.28
46,971.55
28,184.13
19,665.08
15,790.49
11,873.08
8,862.13
8,072.76
Net Block
18,852.65
17,675.17
15,872.25
12,682.47
6,817.28
5,647.47
3,951.35
3,293.35
1,938.82
1,787.88
Gross Block
26,948.81
24,466.42
22,180.41
20,406.89
10,485.12
8,709.22
6,448.66
5,319.27
2,740.07
2,472.95
Accumulated Depreciation
8,096.16
6,791.25
6,308.16
7,724.42
3,667.84
3,061.75
2,497.31
2,025.92
801.25
685.07
Non Current Assets
30,473.12
25,963.77
22,439.98
18,055.80
9,497.56
8,161.89
5,496.96
4,279.84
3,567.95
3,004.28
Capital Work in Progress
2,465.16
2,801.38
2,175.45
2,038.61
841.54
562.61
344.65
235.46
144.82
157.10
Non Current Investment
3,052.25
961.00
1,116.07
598.87
787.56
1,106.35
588.96
346.01
1,484.31
1,059.30
Long Term Loans & Adv.
6,052.97
3,844.04
2,322.87
2,631.91
1,016.98
802.56
593.29
377.27
0.00
0.00
Other Non Current Assets
50.09
682.18
953.34
103.94
34.20
42.90
18.71
27.75
0.00
0.00
Current Assets
31,635.90
32,953.65
29,941.30
28,915.75
18,686.46
11,503.03
10,293.37
7,593.05
5,294.18
5,068.48
Current Investments
4,090.62
230.88
713.81
2,117.43
1,998.46
1,305.22
1,623.91
1,883.75
1,682.07
800.19
Inventories
6,880.69
6,832.81
6,422.54
5,667.99
3,123.01
2,577.76
2,086.98
1,489.48
1,073.85
975.70
Sundry Debtors
7,815.28
7,202.61
6,775.66
5,106.13
2,200.42
2,412.23
2,078.74
1,104.87
1,174.77
881.09
Cash & Bank
9,929.38
15,140.84
13,181.65
10,998.04
7,590.15
4,058.71
3,367.19
2,204.63
508.89
1,669.03
Other Current Assets
2,919.93
718.25
530.51
3,105.64
3,774.42
1,149.11
1,136.55
910.32
854.60
742.47
Short Term Loans & Adv.
2,028.62
2,828.26
2,317.13
1,920.52
1,093.74
952.93
976.71
784.37
835.09
685.21
Net Current Assets
11,771.58
15,066.63
16,797.34
12,768.94
12,696.87
8,661.78
7,674.88
5,862.17
4,536.26
4,348.67
Total Assets
62,109.02
58,917.42
52,381.28
46,971.55
28,184.13
19,665.08
15,790.49
11,873.08
8,862.13
8,072.76

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Mar 09
Cash From Operating Activity
3,907.15
7,082.21
6,685.86
5,615.74
3,959.20
3,356.58
2,234.46
2,283.10
781.13
2,164.89
PBT
3,478.98
9,047.87
6,570.63
6,402.90
4,581.17
4,314.89
3,355.36
2,035.95
1,414.84
1,949.17
Adjustment
1,382.22
500.67
1,856.92
773.61
-40.15
160.00
111.12
-171.18
-23.60
381.77
Changes in Working Capital
-212.31
-409.21
246.77
179.59
207.10
-44.83
-1,005.25
487.65
-435.63
2.94
Cash after chg. in Working capital
4,648.89
9,139.33
8,674.32
7,356.10
4,748.12
4,430.06
2,461.23
2,352.42
955.61
2,333.88
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-741.74
-2,057.12
-1,988.46
-1,740.36
-788.92
-1,073.48
-226.77
-69.32
-174.48
-168.99
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-3,370.81
-4,221.60
-4,371.59
-2,865.74
-2,366.76
-2,635.05
-862.71
-1,847.71
-213.74
-1,773.02
Net Fixed Assets
-714.76
-1,217.15
2,214.23
-4,631.67
-380.81
-341.28
-267.49
-212.50
-114.06
-169.39
Net Investments
978.04
3,038.39
3,504.47
-18,860.43
-2,698.19
120.24
-836.36
450.27
-1,357.10
-751.47
Others
-3,634.09
-6,042.84
-10,090.29
20,626.36
712.24
-2,414.01
241.14
-2,085.48
1,257.42
-852.16
Cash from Financing Activity
-1,539.26
-2,285.39
-1,888.53
-1,186.53
506.57
-664.99
-544.39
-804.19
-346.43
-266.62
Net Cash Inflow / Outflow
-1,002.92
575.22
425.74
1,563.47
2,099.01
56.54
827.36
-368.80
220.96
125.25
Opening Cash & Equivalents
8,642.36
8,031.69
7,183.49
4,358.70
2,069.11
1,752.67
810.49
633.87
451.24
325.99
Closing Cash & Equivalent
7,906.45
8,642.36
8,031.69
7,285.56
4,358.70
2,069.11
1,752.67
810.49
672.20
451.24

Financial Ratios

Consolidated /

Standalone
Description
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Mar 09
Book Value (Rs.)
158.80
152.70
137.03
123.49
89.44
72.37
59.08
45.79
37.80
34.01
ROA
4.35%
14.08%
11.39%
14.60%
16.21%
19.61%
22.00%
18.43%
15.91%
26.75%
ROE
7.05%
22.51%
19.32%
24.89%
23.15%
25.53%
28.02%
22.07%
18.11%
31.21%
ROCE
8.42%
21.48%
18.64%
25.06%
25.46%
31.39%
30.13%
23.60%
18.67%
31.64%
Fixed Asset Turnover
1.03
1.35
1.34
1.79
1.70
1.51
1.38
1.44
1.57
2.06
Receivable days
103.47
80.78
76.12
48.20
51.72
71.46
71.49
71.57
91.85
95.89
Inventory Days
94.48
76.61
77.46
57.99
63.92
74.22
80.31
80.48
91.57
72.94
Payable days
92.31
77.57
75.24
52.05
56.33
65.15
64.51
51.06
42.23
38.20
Cash Conversion Cycle
105.64
79.82
78.34
54.14
59.31
80.53
87.29
100.98
141.19
130.62
Total Debt/Equity
0.27
0.27
0.26
0.35
0.14
0.02
0.03
0.04
0.02
0.03
Interest Cover
7.72
23.63
13.56
12.06
104.67
101.13
120.02
28.60
231.06
334.19

News Update


  • Sun Pharma launches Ezallor Sprinkle capsules in US
    15th Jul 2019, 08:54 AM

    Ezallor Sprinkle capsules is used for the treatment of three types of elevated lipid disorders in people

    Read More
  • Sun Pharma inks license agreement with CMS for Cyclosporine
    27th Jun 2019, 15:25 PM

    CMS will pay Sun Pharma an initial upfront payment, regulatory and sales milestone payments, and royalties on net sales, the terms of which are confidential

    Read More
  • Sun Pharmaceutical Industries receives four observations from USFDA for its Halol facility
    22nd Jun 2019, 09:54 AM

    The USFDA conducted a pre-approval inspection (PAl) of company's Halol facility from June 3 to June 11, 2019

    Read More
  • Sun Pharma reports interim results from Phase 2 study of interleukin-23
    14th Jun 2019, 11:42 AM

    The interim analysis revealed that over 71% of patients treated with ILUMYA

    Read More
  • Sun Pharma reports 54% fall in Q4 consolidated net profit
    29th May 2019, 10:59 AM

    The company has reported a standalone net profit of Rs 1068.06 crore for the quarter ended March 31, 2019

    Read More
  • Sun Pharma Inds. - Quarterly Results
    28th May 2019, 17:19 PM

    Read More
  • Sun Pharma's arm to commence distribution of its formulation products in India
    9th Apr 2019, 12:04 PM

    This phased transition is expected to be fully completed by the first quarter of 2019-20

    Read More
  • Sun Pharma launches INFUGEM in US
    8th Apr 2019, 09:13 AM

    INFUGEM is an alcohol-free, clear, colorless, sterile solution of 10mg/mL gemcitabine in 0.9% sodium chloride

    Read More

Source: www.accordfintech.com. Price feed provided by www.nseindia.com and www.bseindia.com value addition by www.accordfintech.com. Intraday data delayed 15 minutes.

DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.